Protalix BioTherapeutics, Inc.
PLX
$1.66
$0.085.06%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 104.53% | -155.73% | 100.68% | 246.89% | 52.06% |
| Total Depreciation and Amortization | 4.05% | 3.59% | 1.52% | 3.13% | -0.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,976.36% | -90.98% | -72.45% | 419.72% | 13.00% |
| Change in Net Operating Assets | -274.95% | 46.62% | -105.91% | 22.21% | -126.62% |
| Cash from Operations | -3.46% | -226.74% | -2.78% | 213.71% | -186.20% |
| Capital Expenditure | -40.85% | 28.00% | -388.51% | 49.42% | 71.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.67% | 99.96% | -172.98% | 255,237.50% | 0.00% |
| Cash from Investing | -40.38% | 97.96% | -175.37% | 11,392.78% | 70.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -19.15% | 39.99% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -19.15% | 39.99% | 117.76% | -- | -- |
| Foreign Exchange rate Adjustments | 150.00% | -114.81% | 2,800.00% | 90.00% | -185.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -417.55% | 96.05% | -290.75% | 205.25% | -206.57% |